Showing results (1691-1700 of 1,799) with videos related to
Sort By:
Pageof 180
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.Cancer Immunology Research|April 19, 2023
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Ettai Markovits, Ortal Harush, Erez N Baruch, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 4, 2009
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patientsMichal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|December 23, 2025
Intra-arterial tenecteplase in acute ischemic stroke after successful endovascular thrombectomy: a meta-analysis of randomized controlled trialsOcílio Ribeiro Gonçalves, Mariana Letícia de Bastos Maximiano, João Vitor Andrade Fernandes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanomaSteven J O'Day, Alexander M M Eggermont, Vanna Chiarion-Sileni, et al.Dermatology and Therapy|November 9, 2023
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, et al.BMJ Open|February 10, 2012
Incentivising safe sex: a randomised trial of conditional cash transfers for HIV and sexually transmitted infection prevention in rural TanzaniaDamien de Walque, William H Dow, Rose Nathan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.Blood Advances|July 10, 2024
CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphomaPriyanka A Pophali, Joshua A Fein, Kwang W Ahn, et al.Pageof 180